ALNYLAM PHARMACEUTICALS, INC. (ALNY) Stock
ALNY has an Alpha Score of 27 out of 100 (poor), computed on Oct 29, 2026 from 3 of 4 sub-scores. 6 members of Congress disclosed 14 trades in ALNY since 2016: 6 purchases and 8 sales, most recently Cory A Booker (sale, Aug 11, 2026). 6 of the hedge funds AlphaScala tracks reported ALNY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $332.37M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 2, 2026. Its trailing P/E ratio is 38.0 and its net margin 16.8% (key statistics as of Oct 22, 2026).
What is ALNY's Alpha Score?
How it works →Alpha Score of 26 reflects poor overall profile with poor momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 29, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded ALNYLAM PHARMACEUTICALS, INC. (ALNY)?
Most recent: Cory A Booker (sale, Aug 11, 2026); records start Oct 13, 2016.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Cory Booker D-NJ · Senate | 2026-08-11 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-05-12 | sale | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2024-01-29 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-01-11 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2023-12-11 | sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | purchase | $15k – $50k |
| Dan Goldman D-NY · House | 2023-01-31 | sale | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2022-09-28 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all ALNY political trades →Which hedge funds own ALNY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.10M | $332.37M | +4% |
| Millennium Management Israel Englander | 316K | $95.13M | -29% |
| Marshall Wace | 260K | $78.21M | -76% |
| Citadel Ken Griffin | 191K | $57.51M | +716% |
| Bridgewater Associates Ray Dalio | 100K | $29.98M | -7% |
| Blackstone | 5K | $1.39M | -47% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ALNYLAM PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Supran Bryan | EVP, CLO and Secretary | SELL | 1.8K | $399K |
| Apr 6, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 56 | $18K |
| Apr 6, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 909 | $300K |
| Apr 6, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 829 | $274K |
| Apr 6, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 293 | $97K |
| Apr 6, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 199 | $66K |
| Apr 2, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 265 | $84K |
| Apr 2, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 359 | $114K |
| Apr 2, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 209 | $67K |
| Apr 2, 26 | Mclaughlin Melissa | Chief Human Resources Officer | SELL | 86 | $27K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are ALNY's key statistics?
Key statistics as of Oct 22, 2026
How does ALNY's valuation compare with the Healthcare sector?
| Metric | ALNY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 38.0 | 27.2 | 99 |
| Net margin | 16.82% | 4.85% | 143 |
| Return on equity | 93.61% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
ALNY price chart
Powered by TradingViewWhat does ALNYLAM PHARMACEUTICALS, INC. do?
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company pioneering the development of novel therapeutics based on RNA interference, or RNAi. RNAi represents a natural biological process of gene silencing that enables the creation of a new class of medicines by targeting and potently silencing specific messenger RNAs to prevent disease-causing proteins from being produced. This approach addresses significant unmet medical needs in areas where traditional small molecules or antibodies fall short, such as respiratory syncytial virus infection, hypercholesterolemia, liver cancers, and other diseases. Alnylam Pharmaceuticals Inc. leads in translating RNAi into innovative medicines, supported by foundational patents, proprietary technology, and strategic alliances with major pharmaceutical partners. The company maintains a broad pipeline of investigational RNAi therapeutics, focusing on transformative treatments for patients with rare and prevalent genetic diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals Inc. drives advancements at the forefront of gene-based drug discovery.